First Myopia Treatment Using STAAR's Visian ICLâ„¢, Conducted in China

Filed in archive Diagnostics , Treatment on August 23, 2006

STAAR Surgical Company (Nasdaq: STAA)'s Visian ICLsâ„¢ (Implantable Collamer lenses) have recently been surgically implanted in China following the product's marketing approval by the State Food and Drug Administration (SFDA) of the People's Republic of China.

The Chinese patients: a nearsighted 35-year-old male journalist with astigmatism, and a severely nearsighted 19-year-old female student, suffering from astigmatism, both experienced significantly improved vision after the procedure conducted by Professor Yuangui Wang on August 9, 2006, at the WJ Army Hospital in Shenzhen.

"The first patient was -9.5D with some astigmatism and the second was -13 with 2.5D of astigmatism before treatment," said Professor Yuangui.

"After we implanted the Visian ICL, the first patient could see 20/15 with both eyes, and the 2nd patient improved to 20/20 the following day, a major improvement that shocked all of the staff.

"These outstanding results didn't really surprise me, however, as I have been following the ICL for a couple of years and had heard of its fast recovery," Professor Yuangui added. "The patients were absolutely delighted with the results."

STAAR's ICL is made of a highly biocompatible Collamer® material and is the only minimally invasive foldable lens of its kind approved for the Chinese commercial market.

Read the full press release.